Search Results - "Rooney, I"

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study by Vuylsteke, P., Huizing, M., Petrakova, K., Roylance, R., Laing, R., Chan, S., Abell, F., Gendreau, S., Rooney, I., Apt, D., Zhou, J., Singel, S., Fehrenbacher, L.

“…Approximately 40% of hormone receptor-positive, HER2-negative breast cancers (BCs) are associated with activating mutations of the phosphatidylinositol…”
Get full text

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study by Dréno, B., Ribas, A., Larkin, J., Ascierto, P.A., Hauschild, A., Thomas, L., Grob, J.-J., Koralek, D.O., Rooney, I., Hsu, J.J., McKenna, E.F., McArthur, G.A.

“…In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free…”
Get full text

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study by Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Guo, Y., Yan, Y., Castro, M., Mulla, S., Flaherty, K., Arance, A.

“…Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether…”
Get full text

25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study by McArthur, G, Larkin, J, Dréno, B, Ascierto, P, Liszkay, G, Maio, M, Mandal´, M, Demidov, L, Stroyakovskiy, D, Thomas, L, De la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Hsu, J, Koralek, D, Rooney, I, Yan, Y, Ribas, A

Get full text

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors by ODonnell, P, Goldman, J.W, Gordon, M.S, Shih, K, Choi, Y.J, Lu, D, Kabbarah, O, Ho, W, Rooney, I, Lam, E.T

Get full text

Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma : CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis by ROONEY, I. A, ATKINSON, J. P, KRUL, E. S, SCHONFELD, G, POLAKOSKI, K, SAFFITZ, J. E, MORGAN, B. P

“…We demonstrate here that CD59, an inhibitor of the membrane attack complex (MAC) of the complement system, is present in cell-free seminal plasma (SP) at a…”
Get full text

The Lymphotoxin-β Receptor Is Necessary and Sufficient for LIGHT-mediated Apoptosis of Tumor Cells by Rooney, Isabelle A., Butrovich, Kris D., Glass, Alison A., Borboroglu, Stephen, Benedict, Chris A., Whitbeck, J.Charles, Cohen, Gary H., Eisenberg, Roselyn J., Ware, Carl F.

“…LIGHT is a tumor necrosis factor (TNF) ligand superfamily member, which binds two known cellular receptors, lymphotoxin-β receptor (LTβR) and the herpesvirus…”
Get full text

Disruption of the anterior-posterior rotator cuff force balance alters joint function and leads to joint damage in a rat model by Reuther, Katherine E., Thomas, Stephen J., Tucker, Jennica J., Sarver, Joseph J., Gray, Chancellor F., Rooney, Sarah I., Glaser, David L., Soslowsky, Louis J.

“…ABSTRACT The rotator cuff assists in shoulder movement and provides dynamic stability to the glenohumeral joint. Specifically, the anterior–posterior (AP)…”
Get full text

Control of the complement system by Liszewski, M K, Farries, T C, Lublin, D M, Rooney, I A, Atkinson, J P

“…The complement system has developed a remarkably simple but elegant manner of regulating itself. It has faced and successfully dealt with how to facilitate…”
Get more information

Biceps Detachment Decreases Joint Damage in a Rotator Cuff Tear Rat Model by Thomas, Stephen J., Reuther, Katherine E., Tucker, Jennica J., Sarver, Joseph J., Yannascoli, Sarah M., Caro, Adam C., Voleti, Pramod B., Rooney, Sarah I., Glaser, David L., Soslowsky, Louis J.

“…Background Pathology in the long head of the biceps tendon often occurs in patients with rotator cuff tears. Arthroscopic tenotomy is the most common…”
Get full text

Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid by ROONEY, I. A, MORGAN, B. P

“…A functional complement system and the potential for its activation are present in human amniotic fluid. We have recently demonstrated that CD59 antigen is…”
Get full text

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1 by Saifuddin, M, Parker, C J, Peeples, M E, Gorny, M K, Zolla-Pazner, S, Ghassemi, M, Rooney, I A, Atkinson, J P, Spear, G T

“…This study investigates whether cell-derived glycosylphosphatidylinositol-linked complement control proteins CD55 and CD59 can be incorporated into HIV-1…”
Get full text

Erratum to: Biceps Detachment Decreases Joint Damage in a Rotator Cuff Tear Rat Model by Thomas, Stephen J., Reuther, Katherine E., Tucker, Jennica J., Sarver, Joseph J., Yannascoli, Sarah M., Caro, Adam C., Voleti, Pramod B., Rooney, Sarah I., Glaser, David L., Soslowsky, Louis J.

Get full text

GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells by Rooney, I A, Heuser, J E, Atkinson, J P

“…We analyzed and compared the properties of three glycosylphosphatidylinositol (GPI)-anchored proteins. CD59, CD55 (both C regulators), and CDw52, and of the…”
Get full text

Membrane attack complex (MAC)-mediated damage to spermatozoa : protection of the cells by the presence on their membranes of MAC inhibitory proteins by ROONEY, I. A, DAVIES, A, MORGAN, B. P

“…Although antibody and complement are known to cause immobilization and killing of spermatozoa in vitro the components of the complement system mediating these…”
Get full text

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation by Dziadziuszko, R., Ahn, M.J., Kelly, K., Popat, S., Wakelee, H.A., Baird, A.M., Rooney, I., Afshari, M., Coleman, S., Zhang, Z., Kiruki, H., Patil, N., Wen, X., Bradley, J.D.

“…Until recently, the standard of care for patients (pts) with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) has been…”
Get full text

Endoscopic palliation and survival in malignant biliary obstruction by WEAVER, S. A, STACEY, B. S. F, HAYWARD, S. J, TAYLOR, G. J, ROONEY, N. I, ROBERTSON, D. A. F

“…Malignant biliary obstruction is a common problem that is regarded as having a poor prognosis and is usually managed with palliation. Our aim was to…”
Get full text

LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial by Arance, A.M., Gogas, H., Dreno, B., Flaherty, K.T., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Ferrucci, P.F., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Yan, Y., Larkin, J.M.G.

“…Treatment for pts with advanced BRAFV600 wt melanoma includes immune checkpoint inhibitors, such as P, an anti–PD-1 antibody. MAPK activation is implicated in…”
Get full text

LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial by Arance, A M, Gogas, H, Dreno, B, Flaherty, K T, Demidov, L, Stroyakovskiy, D, Eroglu, Z, Ferrucci, P F, Pigozzo, J, Rutkowski, P, Mackiewicz, J, Rooney, I, Voulgari, A, Troutman, S, Pitcher, B, Yan, Y, Larkin, J M G

“…Abstract Background Treatment for pts with advanced BRAFV600 wt melanoma includes immune checkpoint inhibitors, such as P, an anti–PD-1 antibody. MAPK…”
Get full text

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial by Arance, A.M., Gogas, H., Dreno, B., Flaherty, K.T., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Ferrucci, P.F., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Yan, Y., Larkin, J.M.G.

Get full text